UNSPSC 51313411: Pemirolast

This classification denotes a mast cell stabilizer with the molecular formula C10H8N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2C09NV773M, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 9-methyl-3-(1h-tetrazol-5-yl)- but generally known as pemirolast, which bears US NIH Compound Identifier 57697. European Medicines Agency schedules Pemirolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09656MIG.

UNSPSC 51313411 Pemirolast is a Commodity code nominally for a single ophthalmic antihistamine product, but recent state and local solicitations tagged to this code show little activity directly aligned with the product itself. Instead, the three opportunities on record involve broader pharmaceutical procurement: naloxone and drug deactivation systems for emergency response, a request for information on direct-to-manufacturer prescription programs, and a multistate cooperative contract for generic pharmaceuticals and over-the-counter products. The code appears to function as a catch-all for miscellaneous pharmaceutical goods rather than a precise product-line classification in state and local procurement practice. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering across multiple states including Oregon). The mix suggests that pharmaceutical procurement at the state and local level spans health departments, cooperative purchasing entities, and agencies managing employee and retiree health benefits.

Recent activity clusters in Florida, Texas, and Minnesota, with the most concrete solicitation being Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The Minnesota MMCAP RFP S1070000015802, posted January 20, 2026 with a deadline of March 26, 2026, sought manufacturers of generic multi-source pharmaceuticals and OTC products to supply through authorized wholesalers, with contract effectiveness July 1, 2026. Texas HHS Commission issued RFI HHS0017013 on April 3, 2026 as exploratory market research on direct-to-manufacturer prescription programs, indicating early-stage procurement planning rather than imminent awards. The code shows limited historical activity and mismatch between its nominal scope and actual solicitation content, signaling either inconsistent code application by issuing bodies or that pharmaceutical procurement activity routes through other UNSPSC categories more frequently.